BioAcyl Corp
BioAcyl Corp |
|
 |
 |
 |
|
Mateus, J., Grifoni, A., Tarke, A., Sidney, J., Ramirez, S. I., & Dan, J. M., et al. (2020). Selective and cross-reactive sars-cov-2 t cell epitopes in unexposed humans. Science. Added by: Dr. Enrique Feoli (05/08/2020, 08:28) Last edited by: Dr. Enrique Feoli (10/02/2022, 18:13) |
 |
| Resource type: Journal Article DOI: 10.1126/science.abd3871 ID no. (ISBN etc.): 0036-8075 BibTeX citation key: Mateus2020 View all bibliographic details  |
Categories: BioAcyl Corp, BioAcyl Corp Subcategories: COVID-19 Vaccines, Cross immunity Creators: Burger, Crotty, da Silva Antunes, Dan, de Silva, Frazier, Greenbaum, Grifoni, Lammers, Mallal, Markmann, Mateus, Peters, Phillips, Premkumar, Quiambao, Ramirez, Rawlings, Rubiro, Sette, Sidney, Smith, Sutherland, Tarke, Weiskopf, Yu Collection: Science |
Views: 2/259
|
| Abstract |
|
Many unknowns exist about human immune responses to the SARS-CoV-2 virus. SARS-CoV-2 reactive CD4+ T cells have been reported in unexposed individuals, suggesting pre-existing cross-reactive T cell memory in 20-50% of people. However, the source of those T cells has been speculative. Using human blood samples derived before the SARS-CoV-2 virus was discovered in 2019, we mapped 142 T cell epitopes across the SARS-CoV-2 genome to facilitate precise interrogation of the SARS-CoV-2-specific CD4+ T cell repertoire. We demonstrate a range of pre-existing memory CD4+ T cells that are cross-reactive with comparable affinity to SARS-CoV-2 and the common cold coronaviruses HCoV-OC43, HCoV-229E, HCoV-NL63, or HCoV-HKU1. Thus, variegated T cell memory to coronaviruses that cause the common cold may underlie at least some of the extensive heterogeneity observed in COVID-19 disease.
|
| Notes |
|
We provide direct evidence that numerous CD4+ T cells that react to SARS-CoV-2 epitopes actually cross-react with corresponding homologous sequences from any of the many different commonly circulating HCoVs, and that these reactive cells are largely canonical memory CD4+ T cells. These findings of cross-reactive HCoV T cell specificities are in stark contrast to HCoV-neutralizing antibodies, which are HCoV species specific and did not show cross-reactivity against SARS-CoV-2 RBD.
Added by: Dr. Enrique Feoli Last edited by: Dr. Enrique Feoli |